While GLP-1 receptor agonists do have central nervous system effects related to appetite regulation, they do not typically cause sedation or drowsiness as a direct pharmacologic effect
Individual response depends on baseline metabolic health, reproductive hormone baseline, and rate of weight loss
Yi K, Liu J, Rong Y, Wang C, Tang X, Zhang X, et al
planned for offering once legally available Expected weight loss: Early trials suggest potent effects, but long-term data still emerging Administration: Once-weekly injection (investigational) Best for: Future option for carefully selected patients under close medical supervision Not sure which is right for you
WHO recommends long-term treatment for obesity with GLP-1s in first-ever guidelines The guidelines highlight a shift to viewing obesity as a chronic illness, but safety evidence for GLP-1s remains limited
They worked by revving up your central nervous system to kill your appetite